Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia

Table 1 Adverse events

Adverse event	Grade 1	Grade 2	Grade3	Grade4	Grade5
Gastrointestinal reaction
Nausea and vomiting	3 (6%)	0	1 (2%)	0	0
Diarrhea	2 (4%)	2 (4%)	0	0	0
Hematochezia	0	1 (2%)	2 (4%)	0	0
Pain
Abdominal pain	1 (2%)	0	0	0	0
Headache	6 (13%)	1 (2%)	0	0	0
Arthralgia and Myalgia	7 (15%)	2 (4%)	0	0	0
Chest pain	2 (4%)	0	0	0	0
Skin and mucosa
Dry	9 (19%)	0	0	0	0
Darkened skin	5 (10%)	0	0	0	0
Alopecia	5 (10%)	0	0	0	0
Rash	1 (2%)	3 (6%)	0	0	0
Other symptoms
Fatigue	3 (6%)	1 (2%)	0	0	0
Tinnitus	1 (2%)	0	0	0	0
Epistaxis	2 (4%)	0	0	0	0
Laboratory test
Leukocytopenia	1 (2%)	1 (2%)	0	0	0
Thrombocytopenia	1 (2%)	0	0	0	0
Hepatic dysfunction	1 (2%)	0	0	0	0

Data are n (%)
Three grade 3 adverse events were observed. One patient stopped treatment for 2 months due to grade 3 gastrointestinal reaction and then returned to regular treatment. The other one had abdominal pain and hematochezia at diagnosis, and grade 3 hematochezia occurred again during consolidation therapy. Her enteroscopy suggested ischemic bowel disease. Her consolidation therapy was subsequently changed to chemotherapy and followed by ATRA for maintenance therapy. The last one also had grade 3 hematochezia in the third cycle of consolidation therapy. His abdominal CT scan and enteroscopy suggested intussusception and ischemic bowel disease

ISSN: 1756-8722